Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved. e198 Abstracts Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved S U N D A Y P O S T E R S POSTER SESSION POSTERS’ SESSION P17: KIDNEY AND RAAS PLASMA LEVELS OF ENDOCAN IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS AS BIOMARKER FOR PREDICTION OF CARDIOVASCULAR DISEASE J. Y. Lee, J. Y. Kong, M. H. Kang, H. S. Hwang, J. S. Kim, T. W. Lee, K. Jeong. Kyung Hee University School of Medicine, Seoul, SOUTH KOREA Objective: Endocan, a proteoglycan which is a potential biomarker of endothelial dysfunction, has been shown to be associated with increased cardiovascular risk. We investigated plasma levels of endocan in patients with end-stage renal disease (ESRD) on hemodialysis to predict the risk of cardiovascular diseases. Design and method: A total of 400 adult patients with ESRD undergoing he- modialysis were prospectively enrolled in 6 tertiary hospitals of South Korea from June 2016 to May 2018. They were observed for development of the cardiovas- cular composite outcomes. We compared clinical characteristics and the plasma levels of endocan between 53 patients with cardiovascular composite outcomes and 347 control patients without cardiovascular composite outcomes, analyzed association between endocan level and clinical characteristics and developed the predictive markers of cardiovascular diseases using Cox proportional-hazard analysis. Results: Previous histories of diabetes, acute coronary syndrome, arrhythmia and congestive heart failure were higher in ESRD patients with the cardiovas- cular composite outcomes than control patients. Patients with cardiovascular composite outcomes showed lower levels of hemoglobin, albumin, and high- density lipoproteins compared with control patients. Higher level of plasma endocan, white blood cells and Ca x P were associated with patients with cardiovascular composite outcomes. Cox proportional-hazard analysis showed that diabetes, ACS, arrhythmia, higher level of plasma endocan, and lower level of HDL were significantly associated with cardiovascular composite out- comes: hazard ratios were 7.88 (1.69 to 36.88) (p = 0.01) for endocan (log pg/mL). The patients with level of endocan >3.24 log pg/mL showed signifi- cantly higher cumulative incidence of the cardiovascular composite outcomes in Kaplan-Meier curve (p < 0.001). Conclusions: Plasma Endocan level can be a useful biomarker for prediction of cardiovascular diseases in patients with ESRD on hemodialysis. FUNCTIONAL STATUS OF KIDNEYS AT PATIENTS WITH ARTERIAL HYPERTENSION (ACCORDING TO THE RUSSIAN FEDERAL REGISTER OF ARTERIAL HYPERTENSION) E. V. Oshchepkova, N. V. Lazareva, I. E. Chazova. National Medical Research of Cardiology, Moscow, RUSSIA Objective: to estimate functional status of kidneys at patients with arterial hyper- tension (AH), who were under the care in primary health care Design and method: The study was carried out with AH Register method (Soft- ware with remote access and specially trained doctors made data inputs from medical records into the Register). A selection of 18,656 patients (pts) with AH from 22 Russian regions in 2010–2016 was analyzed. Among them, there were 38% men (n = 7153) of average age 61.4 ± 12 and 62% women with AH, who were 3.7 years older than men; their age was 62.5 ± 12 correspondingly (p < 0.01). The average level of creatinine accounted for 86.5 ± 15.9 micromole/l. Chronic renal disease (CRD) was estimated according to SCF (by formula MDRD). The data were analyzed with using statistical software STATISTICA 10. Results: Normal kidneys function was observed at 20.1 %; slightly diminished function CRD II – at 54.9 %; CRD III at 24.5% and CRD IV – at 0.5% patients with AH. Cardiovascular diseases frequency at patients with CRD IV vs CRD II increases along with progress of state of CRD coronary heart disease 54.2% vs 34.4%, chronic heart failure 40.3% vs 14.7%, Q myocardial infarction in anamnesis 32% vs 15%, peripheral arterial disease 18% vs 6.4%. Stroke |TIA in anamnesis was more often at patients with CRD IV: 19.4% vs 5.2% at pa- tients with AH and CRD II. Diabetes mellitus frequency increases at patients with CRD IV and accounts for 28% vs 14 % at patients with AH and CRD II. Conclusions: According the Register data, along with progress of state of CRD the cardiovascular diseases, stroke |TIA and diabetes mellitus frequency increases in progress; kidney function de- pression is observed at 24.5 % patients with arterial hypertension CHRONIC NITRIC OXIDE SYNTHASE INHIBITION INCREASES RENAL VASOPRESSIN EFFECTS IN NORMOTENSIVE RAT I. Verzicco 1 , S. Tedeschi 1,2 , E. Barouhiel 1 , G. Graiani 3 , M. Ugolotti 1 , S. Cavazzini 4 , E. Bergamaschi 5 , I. Brusasco 1 , F. Di Spigno 1 , A. Vignali 1 , R. Volpi 1 , S. Perlini 6 , A. Montanari 1 , A. Borghetti 1 , A. Cabassi 1 . 1 Cardiorenal Research Unit, Clinica e Terapia Medica, Dipartimento di Medicina e Chirurgia, Universita di Parma, Parma, ITALY, 2 Cardiology Unit, Ospedale Fidenza Vaio, Parma, ITALY, 3 His- tology Laboratory, Dipartimento di Medicina e Chirurgia, School of Dentistry,